Moderna's Ambitious Growth Plans Amid Regulatory Milestones

Moderna anticipates sales of $2.5 to $3.5 billion next year. The company expects 25% annual growth in revenue from 2026 to 2028, driven by new products. Current year sales are forecasted at $3 to $3.5 billion, its lowest since launching the COVID-19 vaccine in 2020. The company focuses on expanding its product lineup, with significant contributions expected from an RSV vaccine and a combination flu and COVID shot.

Moderna on Thursday projected sales between $2.5 billion and $3.5 billion for next year, with new product launches anticipated to boost annual revenue growth by 25% from 2026 to 2028.

Currently, the vaccine maker expects sales between $3 billion and $3.5 billion for this year, marking its lowest annual revenue since the debut of its COVID-19 vaccine in late 2020. Analysts forecast approximately $3.27 billion and $3.74 billion in revenue for 2024 and 2025, respectively.

Next year's forecast reflects uncertainties in the COVID and RSV markets, as well as expectations for revenue from 10 new products approved by 2027 to begin contributing significantly by 2028. Moderna seeks FDA approval to expand its RSV vaccine for high-risk adults under 60 and is shifting focus to a combination flu and COVID vaccine. The standalone flu vaccine has met immune-response targets and will undergo an efficacy study this year.

(With inputs from agencies.)